Should investors worry about RXRX's earnings?

**Investors should not necessarily worry about RXRX's earnings**, as the company's performance is in line with expectations and the broader biotech sector's characteristics. Here's why:

1. **Revenue Growth**: Recursion Pharmaceuticals has shown significant revenue growth, with a reported increase of 147.6% year-over-year to $26.08 million in Q3 2024, surpassing the consensus estimate of $12.62 million. This indicates a strong market demand for the company's services or products.
2. **Consensus Estimates**: The consensus estimates for Recursion Pharmaceuticals' earnings per share (EPS) for the next year, $1.42, represent an improvement from the current year's consensus estimate of $1.57. This suggests that analysts are optimistic about the company's future profitability.

3. **Analyst Confidence**: Despite the negative EPS estimate for the upcoming quarter, which is -$0.44, the company's last price of $5.76 represents a 27.72% change. This positive momentum could be indicative of investor confidence in the company's long-term potential.
4. **Institutional Interest**: Institutional investors have shown increased interest in Recursion Pharmaceuticals, with significant holdings from Sumitomo Mitsui Trust Holdings Inc. and the New York State Common Retirement Fund. This suggests that these investors believe in the company's strategic direction and growth prospects.
5. **Ongoing Projects and Partnerships**: Recursion Pharmaceuticals has several projects in progress and ongoing collaborations with major pharmaceutical companies, which could lead to future revenue streams and breakthroughs in drug discovery.

In conclusion, while Recursion Pharmaceuticals has not yet reached profitability, its revenue growth, analyst confidence, and strategic partnerships suggest that investors should not worry unduly about the company's earnings. However, as with any investment, it's important to consider the company's financial health, market conditions, and the potential risks associated with the biotech sector.